CYP3A4 Expression in breast cancer and its association with risk factors in mexican women

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 8, 2014, Pages 3805-3809

  Floriano Sanchez, Esau ^a,b   Rodriguez, Noemi Cardenas ^c   Bandala, Cindy ^d   Coballase Urrutia, Elvia ^c   Lopez Cruz, Jaime ^e  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b SEDENA   (Mexico)

^c INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^d INSTITUTO NACIONAL DE REHABILITACIÓN   (Mexico)

^e Service of Pathology Hospital Militar de Especialidades de la Mujer y Neonatologia   (Mexico)

Author keywords

Breast cancer; CYP3A4; Gene environment interactions; Mexico; Protein expression

Indexed keywords

CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; DRINKING BEHAVIOR; EPIDEMIOLOGY; FEMALE; HUMAN; METABOLISM; MEXICO; MIDDLE AGED; OVERWEIGHT; RISK FACTOR; SMOKING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; BREAST NEOPLASMS; CARCINOMA; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; MEXICO; MIDDLE AGED; OVERWEIGHT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; SMOKING;

EID: 84901992599     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.8.3805     Document Type: Article

References (39)

1. Bandala C, Floriano-Sanchez E, Cardenas-Rodriguez N, Lopez-Cruz J, Lara-Padilla E (2012). RNA Expression of cytochrome P450 in Mexican women with breast cancer. Asian Pac J Cancer Prev, 13, 2647-2653.
2. Basseville A, Preisser L, de CarneTrecesson S, et al (2011). Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer, 10, 80-92.
3. Blacam C, Ogunleye AA, Momoh AO, et al (2012). High body mass index and smoking predict morbidity in breast cancer surgery: a multivariate analysis of 26,988 patients from the national surgical quality improvement program database. Ann Surg, 255, 551-555.
4. Bruno RD, Njar VC (2007). Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem, 15, 5047-5060.
5. Canchola AJ, Anton-Culver H, Bernstein L, et al (2012). Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control, [Epub ahead of print].
6. Cardenas-Rodriguez N, Lara-Padilla E, Bandala C, et al (2012). CYP2W1, CYP4F11 and CYP8A1 polymorphisms and interaction of CYP2W1 genotypes with risk factors in Mexican women with breast cancer. Asian Pac J Cancer Prev, 13, 837-846.
7. Chu W, Fyles A (2007). Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis, 28, 2139-2142.
8. Garrido-Latorre EC, Lazcano-Ponce L, Lopez-Carrillo M, et al (1996). Age of natural menopause among women in Mexico city. Int J Gynaecol Obstet, 53, 159-166.
9. Guengerich FP (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol, 39, 1-17.
10. Haas S, Pierl C, Harth V, et al (2006). Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int J Cancer, 119, 1785-1791.
11. Hassan BA, Yusoff ZB (2011). Genetic polymorphisms in the three Malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 12, 185-191.
12. Huang Z, Fasco MJ, Figge HL, et al (1996). Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos, 24, 899-905.
13. Jacquemier JD, Penault-Llorca FM, Bertucci F, et al (1998). Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J Pathol, 184, 130-135.
14. Kim SY, Suzuki N, Santosh Laxmi YR, et al (2003). Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol, 16, 1138-1144.
15. Knaul FM, Lopez Carrillo L, Lazcano Ponce E, et al (2009). Cancer de mama: un reto para la sociedad y los sistemas de salud. Salud Publica Mex, 51, 135-137.
16. LIatrakis G, Iavazzo C, Zervoudis S, et al (2011). The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients. Clin Exp Obstet Gynecol, 38, 225-227.
17. Lopez-Carrillo L, Bravo-Alvarado J, Poblano-Verastegui O, et al (1997). Reproductive determinants of breast cancer in Mexican women. Ann N Y Acad Sci, 837, 537-550.
18. Lopez-Carrillo L (2003). El cancer mamario: epidemiologia y prevencion. In: Tamayo RP. El cancer en Mexico. Mexico, D.F.: El Colegio Nacional, 443-456.
19. Lown KS, Bailey DG, Fontana RJ, et al (1997). Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest, 99, 2545-2553.
20. Mc Fadyen MCE, Melvin WT, Murray GI (2004). Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther, 3, 363-371.
21. Mendez-Estrada RO, Valencia M, Melendez Torres JM (2006). Menarche age in teenagers of the Northwest of Mexico. Arch Latinoam Nutr, 5, 1-3.
22. Michael M, Doherty MM (2007). Drug metabolism by tumours: its nature, relevance and therapeutic implications. Expert Opin Drug, 3, 786-803.
23. Mitra R, Gou Z, Milani M, et al (2011). CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducig nuclear translocation of phospho-Stat3 through biosynthesis of (+)-14, 15-epoxyeicosatrienoin acid (EET). J Biol Chem, 286, 17543-17559.
24. Miyoshi Y, Taguchi T, Kim SJ, et al (2005). Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer, 12, 11-15.
25. Nelson HD, Zakher B, Cantor A, et al (2012). Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med, 15, 635-648.
26. Niwa T, Yabusaki Y, Honma K, et al (1998). Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica, 28, 539-547.
27. Ragin CC, Langevin S, Rubin S, et al (2010). Review of studies on metabolic genes and cancer in populations of African descent. Genet Med, 12, 12-18.
28. Shapiro C, Recht A (2001). Side effects of adjuvant treatment of breast cancer. N Engl J Med, 344, 1997-2008.
29. Shou M, Korzekwa KR, Brooks EN, et al (1997). Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis, 18, 207-214.
30. Sistema Nacional de Informacion en Salud (2012). www.sinais.salud.gob.mx/basesdedatos/estandar.html.
31. Takahara T, Nitta H, Hasegawa Y, et al (2011). Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation-interactions between calcineurin inhibitor. Transplant Proc, 4, 2800-2805.
32. Torres-Mejia G, Cupul-Uicab LA, Allen B, et al (2005). Comparative study of correlates of early age at menarche among Mexican and Egyptian adolescents. Am J Hum Biol, 17, 54-58.
33. Vaclavikova R, Hubackova M, Stribrna-Sarmanova J, et al (2007). RNA expression of cytochrome P450 in breast cancer patients. Anticancer Res, 27, 4443-4450.
34. Wang-Rodriguez J, Cross K, Gallagher S, et al (2002). Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol, 15, 853-861.
35. Weiss J, Haefeli WE (2011). Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol, 68, 1093-1098.
36. World Health Organization (2012). www.who.int/mediacentre/factsheets/fs297/es/index.html.
37. Xing MY, Xu SZ, Shen P (2014). Effect of low-fat diet on breast cancer survival:a meta-analysis. Asian Pac J Cancer Prev, 15, 1141-1144.
38. Zheng W, Jin F, Dunning LA, et al (2001). Epidemiological study of urinary 6beta-hydroxycortisol to cortisol ratios and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 10, 237-242.
39. Zhu BT, Conney AH (1998b). Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res, 58, 2269-2277.